{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:57:53Z","timestamp":1776297473686,"version":"3.50.1"},"reference-count":49,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001787","name":"University of South Australia","doi-asserted-by":"publisher","award":["Cancer Research institute Investment Funding"],"award-info":[{"award-number":["Cancer Research institute Investment Funding"]}],"id":[{"id":"10.13039\/501100001787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,5,25]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Physical health conditions are the leading causes of death in people living with severe mental illness. In particular, the risk of metabolic syndrome; the constellation of abnormalities in weight, blood pressure, blood glucose and lipid levels, is high in this cohort. It has been recognised that commonly prescribed pharmacological agents for mental illness can further amplify the risk of developing metabolic syndrome; therefore, monitoring guidelines are in place for consumers prescribed antipsychotics. However, there is a disconnect between recommended guidelines and current practice. Our study aims to investigate: (1) the feasibility of a community pharmacist-led physical health monitoring for metabolic parameters in consumers with mental illness currently taking second generation antipsychotics and (2) the potential outcomes of the intervention (eg, rates and outcome of referrals to general practitioners, relationship between the pharmacist\u2019s lifestyle counselling advice and change in metabolic parameters).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We propose a longitudinal metabolic monitoring study led by community pharmacists with one-to-one consultations between trained pharmacists and participants at set intervals over a 12-month period. Our primary outcome is to determine the feasibility of the pharmacist-led intervention. The secondary outcome is to explore the overall health outcomes of consumers enrolled in the intervention. This is a mixed-methods study including both quantitative and qualitative outcomes. Qualitative data will be analysed via the process of data immersion, coding and identification of themes. Quantitative outcomes will be analysed using IBM Statistics SPSS software. Univariate descriptive, regression analysis and dependent t-tests will be performed. Statistical significance will be at \u03b1 0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Our study has been approved by the institutional Human Research Ethics Committee (Protocol no: 203433). Findings will be made publicly available in peer-reviewed articles, conference presentations to health professionals, as well as other stakeholders. Protocol V.2.1, August 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12621001435875.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-059573","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T12:02:29Z","timestamp":1655726549000},"page":"e059573","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility of a pharmacist-led physical health monitoring for patients on antipsychotic medications: protocol for a longitudinal study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-9298","authenticated-orcid":false,"given":"Tien Ngoc Thi","family":"Bui","sequence":"first","affiliation":[{"name":"Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hotham","sequence":"additional","affiliation":[{"name":"Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Kelly","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines Network, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-935X","authenticated-orcid":false,"given":"Vijayaprakash","family":"Suppiah","sequence":"additional","affiliation":[{"name":"Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia"},{"name":"Australian Centre for Precision Health, University of South Australia, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"2025121515162946000_12.6.e059573.1","unstructured":"World Health Organization . Schizophrenia, 2020. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia [Accessed 13 Jul 2019]."},{"key":"2025121515162946000_12.6.e059573.2","unstructured":"World Health Organization . Premature death among people with severe mental disorders, 2013. Available: https:\/\/www.who.int\/mental_health\/management\/info_sheet.pdf [Accessed 13 Jul 2020]."},{"key":"2025121515162946000_12.6.e059573.3","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31820bf86e"},{"key":"2025121515162946000_12.6.e059573.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.09.032"},{"key":"2025121515162946000_12.6.e059573.5","first-page":"4","article-title":"Antipsychotic-Induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia","volume":"65 Suppl 7","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"2025121515162946000_12.6.e059573.6","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596"},{"key":"2025121515162946000_12.6.e059573.7","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519030-00002"},{"key":"2025121515162946000_12.6.e059573.8","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412449877"},{"key":"2025121515162946000_12.6.e059573.9","doi-asserted-by":"publisher","DOI":"10.3109\/01612840.2011.569846"},{"key":"2025121515162946000_12.6.e059573.10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5694\/j.1326-5377.2004.tb06443.x","article-title":"Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement","volume":"181","author":"Lambert","year":"2004","journal-title":"Med J Aust"},{"key":"2025121515162946000_12.6.e059573.11","article-title":"Twelve-month prospective randomized study of pharmacists utilizing point-of-care testing for metabolic syndrome and related conditions in subjects prescribed antipsychotics","volume":"16","author":"Schneiderhan","year":"2014","journal-title":"Prim Care Companion CNS Disord"},{"key":"2025121515162946000_12.6.e059573.12","doi-asserted-by":"publisher","DOI":"10.1177\/070674370605100804"},{"key":"2025121515162946000_12.6.e059573.13","unstructured":"Roughead L , Procter N , Westaway K . Medication safety in mental health. Sydney: ACSQHC, 2017."},{"key":"2025121515162946000_12.6.e059573.14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.sapharm.2020.09.001","article-title":"Examining the dispensing patterns of antipsychotics in Australia from 2006 to 2018 - A pharmacoepidemiology study","volume":"17","author":"Claassen","year":"2021","journal-title":"Res Social Adm Pharm"},{"key":"2025121515162946000_12.6.e059573.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.04.010"},{"key":"2025121515162946000_12.6.e059573.16","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2011.tb00036.x"},{"key":"2025121515162946000_12.6.e059573.17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.59.8.847"},{"key":"2025121515162946000_12.6.e059573.18","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/hex.12179","article-title":"Australian mental health consumers' and carers' experiences of community pharmacy service","volume":"18","author":"Knox","year":"2015","journal-title":"Health Expect"},{"key":"2025121515162946000_12.6.e059573.19","unstructured":"El-Den S . Reforming Australian mental health care \u2013 pharmacists\u2019 roles, 2020. Available: https:\/\/www.australianpharmacist.com.au\/reforming-australian-mental-health-care-pharmacists-roles [Accessed 18 Feb 2020]."},{"key":"2025121515162946000_12.6.e059573.20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1715163517745517","article-title":"Pharmacists as accessible primary health care providers: review of the evidence","volume":"151","author":"Tsuyuki","year":"2018","journal-title":"Can Pharm J"},{"key":"2025121515162946000_12.6.e059573.21","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181e57962"},{"key":"2025121515162946000_12.6.e059573.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2006.10.005"},{"key":"2025121515162946000_12.6.e059573.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.09.023"},{"key":"2025121515162946000_12.6.e059573.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2011.04.027"},{"key":"2025121515162946000_12.6.e059573.25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.21.2355"},{"key":"2025121515162946000_12.6.e059573.26","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090656"},{"key":"2025121515162946000_12.6.e059573.27","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.399"},{"key":"2025121515162946000_12.6.e059573.28","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0369"},{"key":"2025121515162946000_12.6.e059573.29","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2012.754463"},{"key":"2025121515162946000_12.6.e059573.30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-282"},{"key":"2025121515162946000_12.6.e059573.31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s11096-014-9964-3","article-title":"Effectiveness of a community pharmacy weight management programme","volume":"36","author":"Boardman","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"2025121515162946000_12.6.e059573.32","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.sapharm.2019.12.016","article-title":"Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: an umbrella review","volume":"16","author":"Newman","year":"2020","journal-title":"Res Social Adm Pharm"},{"key":"2025121515162946000_12.6.e059573.33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1331\/JAPhA.2013.11176","article-title":"Development, implementation, and evaluation of a pharmacist-conducted screening program for depression","volume":"53","author":"Rosser","year":"2013","journal-title":"J Am Pharm Assoc"},{"key":"2025121515162946000_12.6.e059573.34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.sapharm.2014.08.013","article-title":"A feasibility study of community pharmacists performing depression screening services","volume":"11","author":"O'Reilly","year":"2015","journal-title":"Res Social Adm Pharm"},{"key":"2025121515162946000_12.6.e059573.35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/09638237.2017.1340618","article-title":"The impact of a person-centred community pharmacy mental health medication support service on consumer outcomes","volume":"27","author":"McMillan","year":"2018","journal-title":"J Ment Health"},{"key":"2025121515162946000_12.6.e059573.36","first-page":"49","article-title":"The Potential Role of the Pharmacist in Supporting Patients with Depression - A Literature-Based Point of View","volume":"9","author":"Kamusheva","year":"2020","journal-title":"Integr Pharm Res Pract"},{"key":"2025121515162946000_12.6.e059573.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02143.x"},{"key":"2025121515162946000_12.6.e059573.38","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s11096-015-0126-z","article-title":"Developing and testing evidence-based weight management in Australian pharmacies: a healthier life program","volume":"37","author":"Um","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"2025121515162946000_12.6.e059573.39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1331\/JAPhA.2010.08104","article-title":"Establishing a cardiovascular health and wellness program in a community pharmacy: screening for metabolic syndrome","volume":"50","author":"Olenak","year":"2010","journal-title":"Journal of the American Pharmacists Association"},{"key":"2025121515162946000_12.6.e059573.40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s11096-020-01084-3","article-title":"A systematic review of pharmacist input to metabolic syndrome screening, management and prevention","volume":"42","author":"Al AdAwi","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"2025121515162946000_12.6.e059573.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01586-9","article-title":"The role of pharmacy in the management of cardiometabolic risk, metabolic syndrome and related diseases in severe mental illness: a mixed-methods systematic literature review","volume":"10","author":"Sud","year":"2021","journal-title":"Syst Rev"},{"key":"2025121515162946000_12.6.e059573.42","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31816d83e4"},{"key":"2025121515162946000_12.6.e059573.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143697","article-title":"Validation of the Stop-Bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis","volume":"10","author":"Nagappa","year":"2015","journal-title":"PLoS One"},{"key":"2025121515162946000_12.6.e059573.44","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-0903"},{"key":"2025121515162946000_12.6.e059573.45","doi-asserted-by":"publisher","DOI":"10.1080\/08870449908407311"},{"key":"2025121515162946000_12.6.e059573.46","unstructured":"Australian Government . Modified Monash model, 2021. Available: https:\/\/www.health.gov.au\/health-topics\/rural-health-workforce\/classifications\/mmm [Accessed 14 Apr 2022]."},{"key":"2025121515162946000_12.6.e059573.47","doi-asserted-by":"publisher","DOI":"10.1177\/1539449215578649"},{"key":"2025121515162946000_12.6.e059573.48","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2025121515162946000_12.6.e059573.49","first-page":"79","article-title":"How to control confounding effects by statistical analysis","volume":"5","author":"Pourhoseingholi","year":"2012","journal-title":"Gastroenterol Hepatol Bed Bench"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-059573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T23:16:46Z","timestamp":1765840606000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-059573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,20]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2021-059573"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-059573","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}